Investor Update

Reminder: Invitation to Roche’s live audio webcast on efficacy and safety of risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020

We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 6 February 2020, highlighting Roche data on risdiplam in type 2/3 spinal muscular atrophy from the SUNFISH Part 2 trial presented at the 2nd International Scientific Congress on spinal muscular atrophy, (5 - 7 Feb) in Evry, France. Agenda: Welcome Karl Mahler, Head of Investor Relations   Phase II/III SUNFISH part 2 data - efficacy and safety of risdiplam in patients with type 2 or type 3 SMA Paulo Fontoura, Global Head Neuroscience and Rare Diseases Clinical Development   Q&A Please dial in as outlined below: 15:00 – 15:45 CET / 14:00 - 14:45 GMT 09:00 – 09:45 am EST / 06:00 - 06:45 am PST Audio webcast and conference call will start with presentations followed by a Q&A session (live access to the speakers). Access to Audio webcast Please access by clicking on > ir.roche.com Access to Conference Call (pre-registration required) You will receive phone numbers, passcode and your personal PIN to direct access the conference call by pre-registering here. Should you have any issues with the registration, please dial the following numbers on the day of the conference call 10-15 minutes prior to conference start: +41 (0) 58 310 50 00 (Europe & RoW)  +44 (0) 207 107 0613 (UK) +1 631 570 56 13 (USA) A replay of the webcast will be available via > ir.roche.com